期刊文献+

由骨髓增生异常综合征转化伴稀有融合基因混合谱系白血病-AFX急性髓系白血病的研究

原文传递
导出
摘要 目的对1例由骨髓增生异常综合征(MDS)转化伴稀有融合基因混合谱系白血病(MLL)-AFX的急性髓系白血病(AML)患者进行确诊。方法骨髓涂片及多重反转录聚合酶链反应(RT-PCR),检测患者骨髓原始细胞比例及融合基因的表达。结果患者骨髓单个核细胞中检测到稀有融合基因MLL—AFX的表达。结论该例患者为MDS转化伴稀有融合基因MLL-AFX的AML,患者预后差。
出处 《白血病.淋巴瘤》 CAS 2013年第4期236-238,共3页 Journal of Leukemia & Lymphoma
基金 江苏省临床医学中心(ZX201102) 国家自然科学基金(81170468) 江苏省自然科学基金(BK2011266)
  • 相关文献

参考文献26

  • 1Rowley JD. The role of chromosome translocations in leukemogenesis. Semin Hematol, 1999, 36: 59-72.
  • 2Helm S, Mitelman F. Cancer cytogenetics: Chromosomal and molecular aberrations of tumor ceils. 2nd edn. New York: Wiley and Sons, 1995.
  • 3Second MIC Cooperative Study Group: Morphologic, immunologic and cytogenetic (MIC) working classification of the acute myeloid leukaemias. Br J Haematol, 1988, 68: 487-494.
  • 4Felix CA, Lange BJ. Leukemia in infants. Oneologist, 1999, 4: 225-240.
  • 5Tamai H, Inokuehi K. llq23/MLL acute leukemia: update of clinical aspects. J Clin Exp Hematop, 2010, 50: 91-98.
  • 6姜丽波,张淑英,韩树林,周虹,曲延章,郭珩,王苏亮.急性髓细胞性白血病核型与预后相关性分析[J].白血病.淋巴瘤,2010,19(5):305-306. 被引量:1
  • 7Mitelman F, Johansson B, Mertens F. Mitelman database of chromosome aberrations in cancer. Updated August 2003. http://egap. nci.nih.gov/C hromosomes/Mitelman.
  • 8Pallisgaard N, Hokland P, Riishcj DC, et al. Multiplex reverse transcfiption-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood, 1998, 92: 574-588.
  • 9蔡佳翌,陈芳源,钟济华,钟华,王海嵘.HAG方案促白血病细胞株凋亡的机制[J].白血病.淋巴瘤,2011,20(12):712-715. 被引量:1
  • 10张天佼(综述),肖志坚(审校).老年急性髓系白血病治疗进展[J].白血病.淋巴瘤,2010,19(9):573-576. 被引量:2

二级参考文献42

  • 1张晓燕,夏震,李军民,陈冰,王晓敏,沈志祥,陈赛娟.急性髓细胞性白血病核型与预后相关性的观察[J].诊断学理论与实践,2004,3(6):438-441. 被引量:1
  • 2邵英起,刘世和,徐世才,徐泽锋,李睿,邱录贵,郝玉书,肖志坚.261例急性髓系白血病的WHO分型[J].白血病.淋巴瘤,2005,14(3):129-132. 被引量:5
  • 3秘营昌,薛艳萍,俞文娟,刘世和,赵耀中,孟庆祥,卞寿庚,王建祥.HA为基础的三药方案治疗急性髓系白血病疗效分析及与染色体核型的关系[J].中华血液学杂志,2005,26(12):705-709. 被引量:19
  • 4胥彬,卢大用,袁兆康,张树东.高三尖杉酯碱对HL_(60)细胞诱导分化与对细胞膜通道影响相互关系的研究[J].天然产物研究与开发,1996,8(3):13-16. 被引量:4
  • 5之南.血液病诊断及疗效标准.2版.北京:科学出版社,1998:171-218.
  • 6Slovak ML Kopecky KJ,Cassileth PA,et al.Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia:a Southwest Oncology Group/Eastern Cooperative Oneoiogy Group Study.Blood.2000.96:4075-4083.
  • 7Byrd JC,Mrózek K,Dedge RK,et lt.pretreatment cytogenetic abnormalities are predictive of induction success,cumulative incidence,of relapse,and overall survival in adult patients with de novo acute myeloid leukemia:results from Cancer and Leukemia Group B(CALGB 8461).Blood,2002,100:4325-4336.
  • 8Laubach J,Rao AV.Current and emerging strategies for the management of aaute myeloid leukemia in the elderly.Oncologist,2008,13:1097-1108.
  • 9Rao AV,Valk P,Metzeler KH,et al.Age-specific differences in oncogenic pathway dysregulation and anthracyclinesensitivity in patients with acute myeloid leukemia.J Clin Oncol,2009,27:5580-5586.
  • 10Baz R,Rodriguez C,Fu AZ,et al.Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia.Cancer,2007,110:1752-1759.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部